Ben Edwards is chief operating officer at Avance Clinical.
Early-phase clinical trials are becoming more complex and data-driven, requiring emerging biotechs to incorporate biomarker strategies, exposure–response analyses, and regulatory planning into Phase I study design while carefully considering CRO selection, operational continuity, and trial geography.
Advanced data strategies and specialist biometrics teams can deliver faster, cleaner insights from Phase I trials and power smarter early drug decisions, says Ben Edwards of Avance Clinical.
Avance Clinical’s Ben Edwards explains how biotechs must design Phase I trials for quantitative exposure–response data to meet current FDA guidance and de‑risk Phase II dose selection.
